Manufacturing quality and costs always play some part in the cost of a new drug, but they are the elephant in the room when looking at CAR-T, personalized cancer medications now under development.

U.S. manufacturing was steady in February, but a measure of prices at the factory gate jumped to near a three-year high and it was taking longer for materials to be delivered, suggesting that tariffs ...

The US Food and Drug Administration (FDA) has launched a new scheme that will streamline the introduction of new pharmaceutical manufacturing facilities in the US, a strategy in line with US President ...